Johnson & Johnson (NYSE:JNJ) is one of the best companies in the US in terms of returning capital to shareholders. Management makes buying back stock and paying dividends a collective priority and the formula has worked; dividend investors in particular can't get enough of JNJ's capital returns. The dividend is a big piece of it but the buyback consumes about the same amount of money as the dividend on average, making the effectiveness of it a priority for holders as well. In this article, I'll take a look at what JNJ has spent buying back stock and what it has to show for it.
Johnson & Johnson Has Let Shareholders Down
3/21/17
By Josh Arnold, SeekingAlpha
Stories you Need to Know
- David Nevins Interviews Dr. Matthew Frieman, Associate Professor, University of Maryland School of Medicine
- Amneal Reports Fourth Quarter and Full Year 2020 Financial Results
- Insmed Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
- Provention Bio Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
- Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial and Operational Results
- Pacira BioSciences Reports Full-Year and Fourth Quarter 2020 Financial Results
- MTBC Reports Record Full Year 2020 Results
- Aclaris Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides a Corporate Update
- Merck to Acquire Pandion Therapeutics
- Madrigal Pharmaceuticals Reports 2020 Fourth Quarter and Full Year Financial Results and Highlights

